Apabetalone demonstrates a positive effect on major CV events in patients with chronic kidney disease.- Resverlogix Corporation

Resverlogix Corp. announced the recent publication of an article titled: “Effect of Apabetalone on Major Adverse Cardiovascular Events in Patients with Chronic Kidney Disease, Type-2 Diabetes Mellitus and Recent Acute Coronary Syndrome: Results from the BETonMACE Randomized Controlled Trial” , in the high-impact, peer-reviewed Clinical Journal of the American Society of Nephrology. The article was accompanied by a peer-reviewed editorial, published in the same journal, titled: “Novel Therapeutic Options for Cardiovascular Disease with CKD”. Publication Highlights include : i. In a pre-specified analysis in patients with CKD, participants in the placebo group with CKD experienced double the incidence of MACE (defined as cardiovascular death, nonfatal myocardial infarction, stroke, and hospitalization for congestive heart failure) than those without CKD. ii. Apabetalone treatment was associated with a 52% hazard reduction for MACE events such as CVD death and Heart Failure, compared to placebo (p=0.03); early and progressive separation in events occurred between the two groups. iii.A statistically significant reduction in alkaline phosphatase, a reported risk marker for CKD, was observed in patients with CKD after 24 weeks of apabetalone treatment (p=0.004). iv. In addition, fewer serious adverse events were also observed in the apabetalone treated group compared to placebo (p=0.02). See-"Effect of Apabetalone on Cardiovascular Events in Diabetes, CKD, and Recent Acute Coronary Syndrome Results from the BETonMACE Randomized Controlled Trial": Kamyar Kalantar-Zadeh, Gregory G. Schwartz, and on behalf of the BETonMACE Investigators. CJASN April 2021, CJN.16751020; DOI: https://doi.org/10.2215/CJN.16751020. (Clinical Journal of the American Society of Nephrology).